- Home
- WLDN vs ABUS Comparison
WLDN vs ABUS Comparison
Compare WLDN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLDN
- ABUS
- Stock Information
- Founded
- WLDN 1964
- ABUS 2005
- Country
- WLDN United States
- ABUS United States
- Employees
- WLDN N/A
- ABUS N/A
- Industry
- WLDN Military/Government/Technical
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- WLDN Consumer Discretionary
- ABUS Health Care
- Exchange
- WLDN Nasdaq
- ABUS Nasdaq
- Market Cap
- WLDN 826.2M
- ABUS 685.7M
- IPO Year
- WLDN 2006
- ABUS N/A
- Fundamental
- Price
- WLDN $67.82
- ABUS $3.19
- Analyst Decision
- WLDN Strong Buy
- ABUS Strong Buy
- Analyst Count
- WLDN 2
- ABUS 4
- Target Price
- WLDN $49.00
- ABUS $5.50
- AVG Volume (30 Days)
- WLDN 223.3K
- ABUS 819.9K
- Earning Date
- WLDN 07-31-2025
- ABUS 07-31-2025
- Dividend Yield
- WLDN N/A
- ABUS N/A
- EPS Growth
- WLDN 79.39
- ABUS N/A
- EPS
- WLDN 1.68
- ABUS N/A
- Revenue
- WLDN $595,695,000.00
- ABUS $6,403,000.00
- Revenue This Year
- WLDN N/A
- ABUS $3.35
- Revenue Next Year
- WLDN $9.94
- ABUS N/A
- P/E Ratio
- WLDN $40.27
- ABUS N/A
- Revenue Growth
- WLDN 12.40
- ABUS N/A
- 52 Week Low
- WLDN $28.72
- ABUS $2.71
- 52 Week High
- WLDN $68.52
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- WLDN 87.52
- ABUS 40.61
- Support Level
- WLDN $58.00
- ABUS $3.04
- Resistance Level
- WLDN $59.37
- ABUS $3.65
- Average True Range (ATR)
- WLDN 2.10
- ABUS 0.14
- MACD
- WLDN 0.52
- ABUS -0.04
- Stochastic Oscillator
- WLDN 94.82
- ABUS 24.59
About WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.